Navigation Links
John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting
Date:6/4/2010

egy.

Is the Mantle Cell Lymphoma International Prognostic Index (MIPI) adequate to stage this cancer? (Abstract number 8092; poster session, June 5, 8:00 a.m. 12:00 p.m.)

In this study, Anthony Mato, M.D., Attending, Lymphoma, the John Theurer Cancer Center and his colleagues looked at the usefulness of a tool known as the Mantle Cell Lymphoma International Prognostic Index (MIPI) for guiding treatment strategies for mantle cell lymphoma, a difficult-to-treat non-Hodgkin lymphoma. The index is used to classify patients into "low," "intermediate" and "high" risk groups in order to stage the cancer and determine the best treatment strategy. Although MIPI has been validated in other studies, conflicting results on using MIPI to guide an aggressive therapy known as "HCVAD" led the researchers to investigate further. They conducted a single-center, retrospective cohort study to identify predictors of survival in patients treated with first-line rituximab-plus-HCVAD (R-HCVAD), alternating with rituximab-methotrexate-AraC (R-MTX-AraC), another combination therapy.

Although the study is still ongoing, the researchers found that MIPI did not identify the three distinct staging categories with respect to patients' overall survival or progression-free survival, the primary endpoints for this study. Dr. Mato and colleagues are collaborating with another center to verify their results. Future work will focus on identifying molecular markers for failure in mantle cell lymphoma patients treated with dose-intensive regimens.

Vorinostat proves safe and tolerable for treating various cancers. (Abstract number e13600; publication-only abstract)

David S. Siegel, M.D., Ph.D., Co-Chief, Multiple Myeloma at the John Theurer Cancer Center and colleagues will present their analyses of safety and tolerability data from Phase I and II studies of vorinostat. Vorinostat is a medication that is FDA approved to treat skin problems rel
'/>"/>

Contact: Amy Leahing
amy.leahing@widmeyer.com
646-213-7245
John Theurer Cancer Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO
2. John Theurer Cancer Center offers breakthrough radiation measurement technology
3. John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients
4. Researchers at the John Theurer Cancer Center Present Cutting-Edge Research Results at this Years American Society of Hematology Annual Meeting
5. AACR Adds to Growing STAR P-2 trial; Publishes Update and Perspectives in Cancer Prevention Research
6. Stage II and stage III colon cancer patients treated after 1995 have improved overall survival
7. Cysts hold clues to pancreatic cancer
8. Interruption of Menstrual Cycle by Chemotherapy Associated with Improved Survival in Early Breast Cancer
9. Olive-oil enriched diet helps breast cancer survivors lose more weight
10. Longer Drug Regimen Still Best Against Breast Cancer
11. Sun-induced skin cancer: new discovery permits doctors to assess genetic risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... A new study published by HealthDay News ... " sheds light on a possible new treatment option for people living with fibromyalgia ... HBOT sessions, at least five per week, patients experienced a significant decrease in pain, ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... There has ... most people think of highways, bridges and railroads, often overlooked is the over ... our homes and buildings and into sewage treatment facilities. According to the American ...
(Date:7/28/2015)... ... July 28, 2015 , ... Please join us for the 5th Annual Step for Hope ... at Gary Avenue and Lies Road in Carol Stream. All are welcome. , Now ... provide education and help to support individuals and families affected by a brain aneurysm. ...
(Date:7/28/2015)... ... July 28, 2015 , ... American Sentinel University has been ... for Geisinger Health System (GHS), one of the nation’s largest integrated health ... nurses with access to American Sentinel’s affordable, flexible and CCNE-accredited RN to BSN ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Scientel ... NoSQL Now! Conference, August 18-20 at the McHenry Convention Center in San Jose, ... in booth #104. , Scientel’s presentation on Multi-Modeling and the industry’s first polymorphic database ...
Breaking Medicine News(10 mins):Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 3Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 3Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 4Health News:Scientel Selected to Present at 2015 NoSQLNow! Conference, San Jose August 18-20 2Health News:Scientel Selected to Present at 2015 NoSQLNow! Conference, San Jose August 18-20 3
... Lower potassium levels in the blood may help explain why ... 2 diabetes as whites, according to a new study by ... part of diabetes prevention may someday prove as easy as ... mean people should run out and start taking potassium supplements," ...
... 2 (HealthDay News) -- Babies born to women who smoke ... have a congenital heart defect than are the offspring of ... increased risk ranged from 20 percent to 70 percent, varying ... that obstruct the flow of blood from the right side ...
... Reporter , TUESDAY, March 1 (HealthDay News) -- On ... Administration approves medical devices with too little oversight comes ... without being adequately tested on women, despite an agency ... heart valves, pacemakers, defibrillators and stents get implanted in ...
... The National Eye Institute (NEI) and Food and Drug ... functional vision-related endpoints for clinical trials of visual prostheses ... visual acuity, visual fields and contrast sensitivity. These assessments ... test outcomes. Today, functional vision outcomes ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, March 1 ... some people of white European descent who have type 2 diabetes. ... may prove a future target for treatments, among other benefits, say ... Journal of the American Medical Association . As with ...
... , TUESDAY, March 1 (HealthDay News) -- A new international ... States and elsewhere may be infected with human papillomavirus (HPV), ... tumors. The finding could help public health experts ... study authors say. "The incidence of genital HPV infection ...
Cached Medicine News:Health News:Potassium levels possible key to racial disparity in Type 2 diabetes 2Health News:Smoking During Early Pregnancy May Put Baby's Heart at Risk 2Health News:Heart Devices Not Tested Enough in Women: Study 2Health News:Heart Devices Not Tested Enough in Women: Study 3Health News:Visual prostheses: Symposium to explore combining functional endpoints 2Health News:Scientists Spot Another Gene Behind Type 2 Diabetes 2Health News:Half of U.S. Men Infected With HPV, Study Reveals 2
(Date:7/27/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... subscriptions from institutional and accredited investors for a ... of common stock and 3.35 million common stock ...
(Date:7/27/2015)... 27, 2015 Bloomage BioTechnology Corporation Limited ("Bloomage" ... cooperation with the South Korean BioTech Company Medytox Inc. ... Medybloom to develop and promote Type A Botulinum Toxin ... Medytox, the Botulinum Toxin brand, occupies ... the fourth company in the world successfully developed and ...
(Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3
... BEVERLY, Mass., March 8, 2011 Cellceutix Corporation (Pink ... has entered into a Confidential Disclosure Agreement (CDA) pertaining ... world,s largest pharmaceutical companies. Cellceutix CEO, ... to be signing a CDA on a compound before ...
... Inc. (Nasdaq: CPIX ), a specialty pharmaceutical ... announced fourth quarter and full year 2010 financial results. ... December 31, 2010, net revenue was $12.8 million, up 20% ... quarterly revenue growth was largely driven by 16% year-over-year growth ...
Cached Medicine Technology:Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 2Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 2Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 4Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 5Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 6Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 7Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 8Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 9Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 10Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 11Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 12Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 13
"Ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Complies with international standards of electrophysiology....
... Slit Lamp is the ideal instrument combination: in ... handy slit lamp to an indirect ophthalmoscope. ... anterior and posterior ocular segments, the HSO 10 ... in miniature. Outstanding benefits for your work include ...
... Analyzers Model 350 and Model 360 ... lensometry for your practice. ,Simple to ... gives fast and accurate lens neutralization ... lenses, contact lenses, polycarbonate and other ...
... contains a plunger style advance, or a ... for multiple use. The injector is made ... STAAR cartridges. These injectors are sold sterile, ... This system was designed specifically for easy ...
Medicine Products: